Erratum: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation (Clinical Cancer Research (2021) 27 (6366–6375) DOI: 10.1158/1078-0432.CCR-20-4185)

Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia M. LoRusso, Joseph P. Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron H.J. Mathijssen, Jaap Verweij, Ingmar Bruns, Martijn P. Lolkema

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Erratum: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation (Clinical Cancer Research (2021) 27 (6366–6375) DOI: 10.1158/1078-0432.CCR-20-4185)'. Together they form a unique fingerprint.

Medicine & Life Sciences